Rituxmab Versus IL-6 in Treating ILD

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

June 1, 2023

Conditions

Interstitial Lung DiseaseScleroderma

Interventions

DRUG

Rituximab

IV infusion 1000 mg

DRUG

IL6 inhibitor

6 mg/kg I V infusion monthly

Trial Locations (1)

Manal Hassanien, Asyut

All Listed Sponsors

lead

Assiut University

OTHER

NCT05963048 - Rituxmab Versus IL-6 in Treating ILD | Biotech Hunter | Biotech Hunter